"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 5 | 5 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 7 | 7 |
| 2004 | 0 | 9 | 9 |
| 2005 | 0 | 8 | 8 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 7 | 7 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 6 | 6 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 9 | 9 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 5 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 4 | 3 | 7 |
| 2018 | 3 | 2 | 5 |
| 2019 | 2 | 3 | 5 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
-
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1776-1787.
-
Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
-
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 Oct; 167(5):919-933.
-
Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Inflamm Bowel Dis. 2023 05 02; 29(5):695-704.
-
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2023 01; 57(1):150-151.
-
CD4+ T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-a/Tumor Necrosis Factor Receptor 1-Dependent. Am J Respir Crit Care Med. 2022 06 15; 205(12):1403-1418.
-
Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis. Dig Dis Sci. 2022 03; 67(3):805-809.
-
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. Dig Dis. 2022; 40(5):553-564.
-
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11).